S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:DTIL

Precision BioSciences Competitors

$11.50
+0.48 (+4.36 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.80
Now: $11.50
$11.55
50-Day Range
$10.39
MA: $12.68
$15.79
52-Week Range
$4.45
Now: $11.50
$16.60
Volume920,289 shs
Average Volume1.18 million shs
Market Capitalization$603.52 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08

Competitors

Precision BioSciences (NASDAQ:DTIL) Vs. KYMR, ALVR, BCRX, VCEL, BLUE, and SRRK

Should you be buying DTIL stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Precision BioSciences, including Kymera Therapeutics (KYMR), AlloVir (ALVR), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), bluebird bio (BLUE), and Scholar Rock (SRRK).

Kymera Therapeutics (NASDAQ:KYMR) and Precision BioSciences (NASDAQ:DTIL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Profitability

This table compares Kymera Therapeutics and Precision BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kymera TherapeuticsN/AN/AN/A
Precision BioSciences-484.81%-105.74%-53.08%

Institutional & Insider Ownership

37.8% of Kymera Therapeutics shares are held by institutional investors. Comparatively, 48.6% of Precision BioSciences shares are held by institutional investors. 14.3% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Kymera Therapeutics and Precision BioSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kymera Therapeutics02402.67
Precision BioSciences02402.67

Kymera Therapeutics presently has a consensus target price of $50.3333, suggesting a potential upside of 4.47%. Precision BioSciences has a consensus target price of $20.00, suggesting a potential upside of 73.91%. Given Precision BioSciences' higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Kymera Therapeutics.

Earnings & Valuation

This table compares Kymera Therapeutics and Precision BioSciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera TherapeuticsN/AN/AN/AN/AN/A
Precision BioSciences$22.24 million27.14$-92,880,000.00($1.91)-6.02

Kymera Therapeutics has higher earnings, but lower revenue than Precision BioSciences.

Summary

Precision BioSciences beats Kymera Therapeutics on 4 of the 7 factors compared between the two stocks.

Precision BioSciences (NASDAQ:DTIL) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Precision BioSciences and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precision BioSciences-484.81%-105.74%-53.08%
AlloVirN/AN/AN/A

Institutional & Insider Ownership

48.6% of Precision BioSciences shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 14.3% of Precision BioSciences shares are owned by company insiders. Comparatively, 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Precision BioSciences and AlloVir, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precision BioSciences02402.67
AlloVir00403.00

Precision BioSciences presently has a consensus price target of $20.00, suggesting a potential upside of 73.91%. AlloVir has a consensus price target of $48.75, suggesting a potential upside of 59.73%. Given Precision BioSciences' higher possible upside, research analysts clearly believe Precision BioSciences is more favorable than AlloVir.

Earnings and Valuation

This table compares Precision BioSciences and AlloVir's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision BioSciences$22.24 million27.14$-92,880,000.00($1.91)-6.02
AlloVirN/AN/AN/AN/AN/A

AlloVir has lower revenue, but higher earnings than Precision BioSciences.

Precision BioSciences (NASDAQ:DTIL) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Volatility and Risk

Precision BioSciences has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 3.03, meaning that its share price is 203% more volatile than the S&P 500.

Profitability

This table compares Precision BioSciences and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precision BioSciences-484.81%-105.74%-53.08%
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%

Institutional & Insider Ownership

48.6% of Precision BioSciences shares are owned by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 14.3% of Precision BioSciences shares are owned by company insiders. Comparatively, 4.3% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Precision BioSciences and BioCryst Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precision BioSciences02402.67
BioCryst Pharmaceuticals03802.73

Precision BioSciences presently has a consensus price target of $20.00, suggesting a potential upside of 73.91%. BioCryst Pharmaceuticals has a consensus price target of $11.3750, suggesting a potential upside of 2.02%. Given Precision BioSciences' higher possible upside, research analysts clearly believe Precision BioSciences is more favorable than BioCryst Pharmaceuticals.

Earnings and Valuation

This table compares Precision BioSciences and BioCryst Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision BioSciences$22.24 million27.14$-92,880,000.00($1.91)-6.02
BioCryst Pharmaceuticals$48.83 million40.54$-108,900,000.00($0.94)-11.86

Precision BioSciences has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Summary

BioCryst Pharmaceuticals beats Precision BioSciences on 8 of the 14 factors compared between the two stocks.

Precision BioSciences (NASDAQ:DTIL) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Volatility and Risk

Precision BioSciences has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, meaning that its share price is 211% more volatile than the S&P 500.

Profitability

This table compares Precision BioSciences and Vericel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precision BioSciences-484.81%-105.74%-53.08%
Vericel0.12%0.13%0.10%

Institutional & Insider Ownership

48.6% of Precision BioSciences shares are owned by institutional investors. Comparatively, 93.1% of Vericel shares are owned by institutional investors. 14.3% of Precision BioSciences shares are owned by company insiders. Comparatively, 4.3% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Precision BioSciences and Vericel, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precision BioSciences02402.67
Vericel02602.75

Precision BioSciences presently has a consensus price target of $20.00, suggesting a potential upside of 73.91%. Vericel has a consensus price target of $49.00, suggesting a potential upside of 15.27%. Given Precision BioSciences' higher possible upside, research analysts clearly believe Precision BioSciences is more favorable than Vericel.

Earnings and Valuation

This table compares Precision BioSciences and Vericel's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision BioSciences$22.24 million27.14$-92,880,000.00($1.91)-6.02
Vericel$117.85 million16.58$-9,660,000.00$0.18236.17

Vericel has higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Precision BioSciences on 10 of the 14 factors compared between the two stocks.

Precision BioSciences (NASDAQ:DTIL) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Volatility and Risk

Precision BioSciences has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Profitability

This table compares Precision BioSciences and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precision BioSciences-484.81%-105.74%-53.08%
bluebird bio-256.84%-45.78%-35.14%

Institutional & Insider Ownership

48.6% of Precision BioSciences shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 14.3% of Precision BioSciences shares are owned by company insiders. Comparatively, 3.6% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Precision BioSciences and bluebird bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precision BioSciences02402.67
bluebird bio013402.24

Precision BioSciences presently has a consensus price target of $20.00, suggesting a potential upside of 73.91%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 138.73%. Given bluebird bio's higher possible upside, analysts clearly believe bluebird bio is more favorable than Precision BioSciences.

Earnings and Valuation

This table compares Precision BioSciences and bluebird bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision BioSciences$22.24 million27.14$-92,880,000.00($1.91)-6.02
bluebird bio$44.67 million43.11$-789,610,000.00($14.31)-2.00

Precision BioSciences has higher earnings, but lower revenue than bluebird bio. Precision BioSciences is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

bluebird bio beats Precision BioSciences on 8 of the 13 factors compared between the two stocks.

Precision BioSciences (NASDAQ:DTIL) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of current ratings for Precision BioSciences and Scholar Rock, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precision BioSciences02402.67
Scholar Rock00503.00

Precision BioSciences presently has a consensus price target of $20.00, suggesting a potential upside of 73.91%. Scholar Rock has a consensus price target of $61.60, suggesting a potential upside of 15.08%. Given Precision BioSciences' higher possible upside, research analysts clearly believe Precision BioSciences is more favorable than Scholar Rock.

Profitability

This table compares Precision BioSciences and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precision BioSciences-484.81%-105.74%-53.08%
Scholar Rock-365.84%-80.16%-41.33%

Institutional & Insider Ownership

48.6% of Precision BioSciences shares are owned by institutional investors. Comparatively, 61.9% of Scholar Rock shares are owned by institutional investors. 14.3% of Precision BioSciences shares are owned by company insiders. Comparatively, 24.6% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Precision BioSciences and Scholar Rock's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision BioSciences$22.24 million27.14$-92,880,000.00($1.91)-6.02
Scholar Rock$20.49 million87.88$-51,000,000.00($1.85)-28.94

Scholar Rock has lower revenue, but higher earnings than Precision BioSciences. Scholar Rock is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Precision BioSciences has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

Summary

Scholar Rock beats Precision BioSciences on 10 of the 14 factors compared between the two stocks.


Precision BioSciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$48.18+4.8%$2.14 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
AlloVir logo
ALVR
AlloVir
1.4$30.52+13.1%$1.99 billionN/A0.00Insider Selling
High Trading Volume
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.15+2.1%$1.98 billion$48.83 million-14.67
Vericel logo
VCEL
Vericel
1.5$42.51+4.9%$1.95 billion$117.85 million-4,251,000.00Analyst Report
Analyst Revision
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.68+2.6%$1.93 billion$44.67 million-2.61Analyst Report
Gap Up
Scholar Rock logo
SRRK
Scholar Rock
1.3$53.53+5.5%$1.80 billion$20.49 million-22.21Upcoming Earnings
News Coverage
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$41.63+6.1%$1.79 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
Translate Bio logo
TBIO
Translate Bio
1.4$22.23+4.2%$1.65 billion$7.80 million-20.78Upcoming Earnings
Analyst Revision
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.74+2.6%$1.64 billionN/A-5.91Analyst Report
Unusual Options Activity
Analyst Revision
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.31+8.5%$1.64 billionN/A-19.95High Trading Volume
News Coverage
Gap Up
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.36+1.1%$1.63 billion$102.43 million-18.93Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$72.74+1.5%$1.61 billionN/A-49.15Earnings Announcement
Analyst Upgrade
Analyst Revision
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.93+1.8%$1.49 billion$35.23 million-16.10Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.87+1.3%$1.39 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$17.07+4.8%$1.36 billion$21.22 million-7.65Analyst Upgrade
News Coverage
Gap Up
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$16.07+1.1%$1.34 billionN/A-3.48Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Immunovant logo
IMVT
Immunovant
1.8$13.51+3.2%$1.32 billionN/A-10.47Increase in Short Interest
PCVX
Vaxcyte
1.8$23.76+0.6%$1.21 billionN/A0.00Upcoming Earnings
Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.83+3.7%$1.15 billion$356.07 million7.76Analyst Report
Gap Up
Cortexyme logo
CRTX
Cortexyme
1.3$37.99+4.3%$1.12 billionN/A-15.83Earnings Announcement
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$29.36+20.3%$1.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$11.12+1.4%$1.09 billion$250,000.00-8.76Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$9.17+0.1%$1.08 billion$32.16 million-10.42Earnings Announcement
Analyst Upgrade
Analyst Revision
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.3$12.56+17.2%$1.02 billionN/A-5.87News Coverage
Gap Up
Inhibrx logo
INBX
Inhibrx
1.7$26.39+0.6%$995.22 millionN/A0.00Upcoming Earnings
Gap Down
Passage Bio logo
PASG
Passage Bio
1.9$19.83+2.0%$910.53 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.10+5.5%$906.51 millionN/A-4.15News Coverage
Gap Up
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.75+2.7%$879.69 million$69.89 million-4.47Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$22.41+3.9%$854.22 millionN/A0.00Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.80+3.0%$828.87 millionN/A-10.25
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$21.11+3.9%$814.93 million$42.74 million-234.56Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.13+2.3%$794.02 million$1.12 million-5.18Analyst Upgrade
Gap Up
Cellectis logo
CLLS
Cellectis
1.3$18.19+6.2%$772.82 million$22.99 million-9.68Earnings Announcement
News Coverage
Gap Down
Vaxart logo
VXRT
Vaxart
1.3$6.02+1.7%$708.96 million$9.86 million-10.20Analyst Report
Analyst Revision
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.76+1.5%$657.51 million$2.51 million-4.10Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$31.54+2.9%$640.89 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.18+0.6%$623.06 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.20+1.3%$608.48 million$150.05 million-2.94
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.21+3.6%$572.36 million$14.75 million-2.24Upcoming Earnings
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$12.60+9.1%$571.96 million$147.87 million-4.19Analyst Upgrade
News Coverage
Gap Up
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$9.40+6.1%$568.22 millionN/A-4.56Upcoming Earnings
News Coverage
Gap Up
Compugen logo
CGEN
Compugen
1.4$8.30+1.6%$567.54 million$17.80 million-22.42Analyst Downgrade
High Trading Volume
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.56+4.5%$559.28 million$13.29 million-10.33Upcoming Earnings
News Coverage
Gap Up
Curis logo
CRIS
Curis
1.3$9.47+3.6%$557.00 million$10 million-11.55Increase in Short Interest
Gap Up
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.3$21.00+2.7%$544.11 millionN/A-6.05
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$8.63+7.5%$533.51 millionN/A-1.26Upcoming Earnings
High Trading Volume
Gap Down
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.57+0.1%$512.46 million$4.36 million-4.74Upcoming Earnings
Increase in Short Interest
Gap Down
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.25+1.6%$469.42 millionN/A0.00Upcoming Earnings
HARP
Harpoon Therapeutics
1.5$17.65+8.4%$447.96 million$5.78 million-8.29Upcoming Earnings
News Coverage
Gap Down
AVROBIO logo
AVRO
AVROBIO
1.7$11.32+6.9%$412.63 millionN/A-3.43Gap Up
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.